Acting Attorney General Todd Blanche has rescheduled medical cannabis to Schedule III, providing 280E tax relief while introducing significant federal oversight through a mandatory DEA buy-back mechanism and new administrative fees. Although the reclassification is effective immediately for medical use, the compliance infrastructure remains undefined, and broader rescheduling for the adult-use market is not expected until at least 2027.

The Feds Are Finally Rescheduling, but the DEA is Sticking Around as a New Business Partner

Apr 23, 2026

Source:

Sue Dehnam

MG Magazine

The federal government is officially shifting gears on cannabis, but as with anything involving Uncle Sam, the devil is in the details. Acting Attorney General Todd Blanche just signed an order moving medical marijuana to Schedule III, a move that finally acknowledges the plant's medicinal value. For the community, this is a massive symbolic victory and a practical win for local businesses, as it effectively kills the dreaded 280E tax rule. This means your favorite dispensaries and cultivators can finally deduct normal business expenses, hopefully leading to more reinvestment in quality and community accessibility.

However, the "fine print" is where things get a bit complicated. Instead of the feds backing off, the DEA is essentially stepping in as a mandatory middleman. Under this new framework, the government will technically take "nominal ownership" of licensed crops through a buy/sell-back system. This involves growers storing harvests in DEA-approved facilities and paying an administrative fee to get their own product back. It’s a strange administrative loop designed to satisfy international treaties, and while it sounds like a lot of red tape, it's the price being paid for that federal Schedule III status.

For the everyday enthusiast, the immediate impact might be subtle. You’ll still be shopping at your local state-licensed shops, but you might notice more standardized labeling or stricter security in the future. The biggest hurdle remains the "prescription vs. recommendation" debate, as Schedule III usually requires a formal prescription, which current state programs don’t use.

While we wait for the broader adult-use hearing on June 29, the industry is entering a transitional phase. We’re trading an old, heavy tax burden for a new, uncertain regulatory one. It’s a leap forward for legitimacy and research, but it’s clear the feds want to keep a very close eye on the garden. Stay patient, stay informed, and keep supporting your local growers as they navigate this new maze.